Last Updated : October 11, 2024
Details
Generic Name:
leuprolide
Project Status:
Pending
Therapeutic Area:
Prostate cancer
Manufacturer:
Accord Healthcare Inc.
Call for patient/clinician input open:
Brand Name:
Camcevi
Project Line:
Reimbursement Review
Project Number:
PC0370-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Camcevi (leuprolide mesylate) is indicated for the treatment of adult patients with advanced prostate cancer.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Camcevi (leuprolide mesylate) is indicated for the treatment of adult patients with advanced prostate cancer.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : October 11, 2024